Tripartite Therapeutics (7920) Stock Overview

Engages in the development of proprietary platform technologies for targeted delivery of therapeutics in Taiwan. More details

7920 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Shares are highly illiquid

Has not reported any financial data

7920 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Tripartite Therapeutics Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Tripartite Therapeutics
Historical stock prices
Current Share Price	NT$14.20
52 Week High	NT$20.60
52 Week Low	NT$5.91
Beta	0
1 Month Change	103.44%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	100.57%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	7920	TW Biotechs	TW Market
7D	15.0%	5.5%	2.8%
1Y	n/a	49.7%	110.4%

Return vs Industry: Insufficient data to determine how 7920 performed against the TW Biotechs industry.

Return vs Market: Insufficient data to determine how 7920 performed against the TW Market.

Price Volatility

Is 7920's price volatile compared to industry and market?
7920 volatility
7920 Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.1%
Market Average Movement	6.3%
10% most volatile stocks in TW Market	12.0%
10% least volatile stocks in TW Market	2.6%

Stable Share Price: 7920's share price has been volatile over the past 3 months compared to the TW market.

Volatility Over Time: Insufficient data to determine 7920's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2009	n/a	Anthony Lin	www.2t-pharma.com

Tripartite Therapeutics Inc. engages in the development of proprietary platform technologies for targeted delivery of therapeutics in Taiwan. Its proprietary OmniLink technology, helps in the therapeutic potential of active pharmaceutical ingredients that were previously limited by toxicities, in vivo stabilities, and unfavorable pharmacokinetic profiles. The company aims to generate a pipeline of treatments for cancer tumors, unmet medical needs in oncology, metabolic diseases, vaccines, and other disease indications.

Tripartite Therapeutics Inc. Fundamentals Summary

How do Tripartite Therapeutics's earnings and revenue compare to its market cap?
7920 fundamental statistics
Market cap	NT$8.38b
Earnings (TTM)	NT$0
Revenue (TTM)	n/a

n/a

P/E Ratio

n/a

P/S Ratio

Is 7920 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
7920 income statement (TTM)
Revenue	NT$0
Cost of Revenue	NT$0
Gross Profit	NT$0
Other Expenses	NT$0
Earnings	NT$0

Last Reported Earnings

n/a

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did 7920 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/06/24 22:28
End of Day Share Price	2026/06/24 00:00
Earnings	N/A
Annual Earnings	N/A

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Tripartite Therapeutics Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.